Form 4: Amylyx Co-CEO Sells Shares for Tax Obligations

Amylyx Pharmaceuticals Co-CEO Justin B. Klee sold 29,975 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Justin B. Klee, Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. (AMLX), reported transactions on September 30, 2025.
• Klee disposed of a total of 29,975 shares of common stock.
• The sales were non-discretionary, executed solely to cover tax withholding obligations associated with the vesting of restricted stock units.
• 29,775 shares were sold at a weighted average price of $14.3728, with individual transaction prices ranging from $13.99 to $14.98.
• An additional 200 shares were sold at a weighted average price of $15.01, with individual transaction prices ranging from $15.00 to $15.02.
• Following these transactions, Klee beneficially owns 3,325,301 shares of Amylyx Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a sale of shares by an insider, it's explicitly stated as non-discretionary and for tax purposes, which is a routine event and not indicative of a lack of confidence in the company's future.

Positives

• The sale was explicitly stated as non-discretionary, solely for tax withholding purposes related to restricted stock unit vesting, indicating it was not a voluntary divestment based on a change in outlook.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if for tax purposes, slightly decreases insider alignment.

Future Outlook

NA

Management Comments

• Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This is a routine insider transaction common across all industries when executives receive equity compensation that vests and triggers tax liabilities. It does not reflect specific industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the non-discretionary nature of the sale mitigates concerns about management confidence.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 reports a non-discretionary sale of shares by a Co-CEO to cover tax obligations related to RSU vesting. Such transactions are routine and do not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Amylyx Pharmaceuticals, AMLX, Justin B. Klee, Form 4, insider transaction, stock sale, tax withholding, restricted stock units, executive compensation